Benzinga | May 20, 2021 07:47AM EDT

Jazz To Present Data At ASCO And EHA 2021 Meetings

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it and its investigator sponsors will present four new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4 -- June 8, 2021 and five abstracts at the virtual 26th Annual Congress of the European Hematology Association (EHA2021) from June 9 --16, 2021. Research findings to be presented include new data on Zepzelca(r) (lurbinectedin), Vyxeos(r)/Vyxeos(r) Liposomal (daunorubicin and cytarabine), also known as JZP351 (formerly known as CPX-351), and Defitelio(r) (defibrotide sodium).

"The unmet needs of patients facing unique challenges and difficult odds drive our research and development objectives, and it's critical for us to continue enhancing our understanding of our existing therapies so that the greatest number of patients can benefit from our innovative medicines," said Robert Iannone, M.D., M.S.C.E., executive vice president, research and development and chief medical officer of Jazz Pharmaceuticals. "We are excited to build upon our growing oncology portfolio and make meaningful strides for more people living with rare or complex hematologic and oncologic diseases."

Highlights from Jazz and its investigational sponsors at the congresses will include:

* A poster presentation at ASCO featuring results from the Phase 1/2 study evaluating the combination of lurbinectedin plus irinotecan in women with endometrial carcinoma.

* A poster presentation featuring preliminary results from V-FAST, a Phase 1b clinical trial evaluating JZP351 in combination with one of three targeted agents (venetoclax, midostaurin or enasidenib) in adults with previously untreated acute myeloid leukemia (AML) who are considered fit for intensive chemotherapy. These data will be presented at both ASCO and EHA.

All ASCO virtual poster presentations and poster discussion presentations will be available on-demand to registered participants for 180 days beginning June 4, 2021. The Jazz-supported and investigational sponsor presentations and publications covering lurbinectedin and JZP351 (formerly known as CPX-351) at the ASCO Annual Meeting are:

Lurbinectedin Presentations

Presentation Title Author Poster Number / Abstract Link

Phase 1/2 Study of Lurbinectedin in Sanchez- Poster Number: 5586 Combination with Irinotecan in Simon I, et Patients Abstract Link al. with Endometrial Carcinoma

Treatment Patterns of Patients with Prince P, et Small Cell Lung Cancer in Second and Publication only al. Third-Line Therapy Settings

Overall Survival of Small Cell Lung Estrin A, Cancer Patients Initiating et Publication only Anti-Cancer al. Treatment

JZP351 (formerly known as CPX-351) Poster Presentation

Presentation Title

Author

Poster Number / Abstract Link

Preliminary Results of V-FAST, a Phase

1B Master Trial to Investigate CPX-351

Combined with Targeted Agents in Newly

Diagnosed AML

Pullarkat V,

et al.

Poster Number: 7026

Abstract Link

The poster presentations and publications covering JZP351 (formerly known as CPX-351) and defibrotide sodium at EHA2021 virtual congress are:

JZP351 (formerly known as CPX-351) Presentations

Presentation Title Author Abstract Code / Abstract Link

Preliminary Results of V-FAST, a Phase 1B Master Trial to Investigate CPX-351 Pullarkat Poster Number: EP442 V, Combined with Targeted Agents in Newly Abstract Link Diagnosed et al. AML

Rapid Genomic Profiling of AML Patients Dolnik A, Poster Number: EP402 with Myelodysplasia-related Cytogenetic et Abstract Link Aberrations (investigator sponsored al. trial)

Pilot Study of CPX-351 in Adults with Relapsed/Refractory Acute Shah BD, Publication only Lymphoblastic Leukemia (investigator et al. sponsored trial)

Defibrotide Sodium Poster Presentations

Presentation Title Author Abstract Code / Abstract Link

Incidence of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Angus J, Poster Number: EP1258 Hematopoietic Cell Transplantation et (HCT) Abstract Link al. in England Based on Healthcare Resource Group Codes and Hospital Episode Statistics(C) Data

EBMT Pass Registry Outcomes of Mohty M, Poster Number: EP1238 Defibrotide-Treated Patients by Timing of et al. Abstract Link Onset of VOD/SOS After HCT

About Vyxeos(r)/Vyxeos(r) Liposomal (daunorubicin and cytarabine), also known as JZP 351

Vyxeos is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.

In the U.S., Vyxeos is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.1